0 8 70 Deap type a plus sign (+) inside this box → +

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Group Art	Unit
1	Examiner	Name

	Substitute for form 1449A/	PTO			Co	mplete if Кл	оwп		P
INI	IEODMATION I	חפרו ר	SUPE A	pplication	n Number	09/518,501			
	· · · · · · · · · · · · · · · · · · ·	ATION DISCLOSURE AP			Filing Date March 3, 2000			. 0	
S	TATEMENT BY	APPL	ICAN I	irst Name	d Inventor	Erion et al.		$\dot{\lambda}$	Z 3.9
				Froup Art U	Jnit	1624		2/4/0	
	(use as many s	sheets as n	ecessary) E	xaminer N	lame	McKenzie,	₹.	EXX.	٠ . د ١٠
Sheet	1	of	1 A	ttorney Do	cket Number	45198.0001	3.RCE (CIP1)		$ \mathcal{C}_{\mathcal{O}_{2}}$
evaminer.	Cite U.S. Patent D	ocument	U.S. PATENT		ate of Publication	01	Pages, Columns,	Lines,	16000000000000000000000000000000000000
	Cite No.1 Number	Ocument Kind Code ² (if known)	U.S. PATENT Name of Patentee or Ap of Cited Document	plicant C		of	Pagas, Columns, Where Releva Passages or Rel Figures Appa	Lines, nt ovant	10.
	Cité	Kind Code ²	Name of Patentee or Ap	plicant t	Date of Publication Cited Document	of	Where Releva Passages or Rele	Lines, nt ovant	10.
	No.1 Number	Kind Code ²	Name of Patentee or Ap of Cited Document	plicant t	Date of Publication Cited Document MM-DD-YYYY	of	Where Releva Passages or Rele	Lines, nt ovant	10.
	No.1 Number 6,054,587	Kind Code ²	Name of Patentee or Ap of Cited Document Reddy et al.	plicant t	Date of Publication Cited Document MM-DD-YYYY 4/25/00	of	Where Releva Passages or Rele	Lines, nt ovant	10.
Examiner Initials*	Number 6,054,587 6,110,903	Kind Code ²	Name of Patentee or Ap of Cited Document Reddy et al. Kasibhatla et al.	plicant t 0	Date of Publication Cited Document MM-DD-YYYY 4/25/00 8/29/00	of	Where Releva Passages or Rele	Lines, nt ovant	10.
	6,054,587 6,110,903 6,284,748	Kind Code ²	Name of Patentee or Ap of Cited Document Reddy et al. Kasibhatla et al. Dang et al.	plicant t 0 0 0 0 0 0	Date of Publication Cited Document MM-DD-YYYY 4/25/00 8/29/00 9/04/01	of	Where Releva Passages or Rele	Lines, nt ovant	10.
	6,054,587 6,110,903 6,284,748 6,294,672	Kind Code ²	Name of Patentee or Ap of Cited Document Reddy et al. Kasibhatla et al. Dang et al. Reddy et al.	Description Column Colum	Date of Publication Cited Document MM-DD-YYYY 4/25/00 8/29/00 9/04/01 9/25/01	of	Where Releva Passages or Rele	Lines, nt ovant	10.

				FOREIGN PA	ATENT DOCUMEN	TS		
Ei	C'i		Foreign Patent Doc		Name of Patenice or	Date of Publication of	Pages, Columns, Lines, Where Relevant	Т
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind Code' (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
-	****							
								T

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²					
			1-					
			╁					
		·						
		·						

Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Praw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Sheet

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Kn wn **Application Number** 09/518,501 INFORMATION DISCLOSURE **Filing Date** March 3, 2000 STATEMENT BY APPLICANT First Named Inventor Erion et al. **Group Art Unit** 1624 (use as many sheets as necessary) Examiner Name T. McKenzie **Attorney Docket Number** 45198.00013.RCE of

·	r		U.S. PATENT DUCU	· · · · · · · · · · · · · · · · · · ·	·
Cite No. ¹	Number -	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					, , , , , , , , , , , , , , , , , , , ,
			<u> </u>		· · · · · · · · · · · · · · · · · · ·
		Cite	No 1 Nurse Kind Code ²	Cite U.S. Patent Document No.1 Number of Patentee or Applicant No.1 Number of Cited Document	No. 1 No. 1 Name of Patentee of Applicant Cited Document

				FOREIGN PA	ATENT DOCUMEN	TS		
Examiner Initials	Cite No.	Office ³	Foreign Patent Doc Number ⁴	ument Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
								+

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	•	FARQUHAR et al., "Synthesis and Antitumor Evaluation of Bis[pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).					
N		LEFEBVRE, et al., Mononucleotide Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine 5'-Monophosphate," J. Med. Chem., 38:3941-3950 (1995).					

Examiner Signature Date Considered 4/16/6

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 2 7

TEN & TRAD

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

7	Substitute for form 1449	-		Co	mplete if Known	
O SIN	IFORMATION	DISC	LOSURE	Application Number	09/518,501	
\$/	TATEMENT O		DUCANT	Filing Date	March 3, 2000	
E 2	TATEMENT B	Y AP	PLICANI	First Named Inventor	Erion et al.	
				Group Art Unit	1624	
	(use as many	/ sheets	as necessary)	Examiner Name	T. McKenzie	
Sheet	1	of	3	Attorney Docket Number	032465.00013.RCE (CIP1)	

				U.S. PATENT DOCU	MENTS	
Examiner	Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,
Initials*	No.'	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
				;		

				FOREIGN PA	ATENT DOCUMEN	ITS		
Examiner	Cite		Foreign Patent Doc	ument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	
Initials*	No.'	Office ³	Number ⁴	Kind Code' (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т
-								1
								Ť

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
8		Beaucage and Iyer, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," <u>Tetrahedron</u> , 49(28):6123-6194 (1993).	
		Borch and Millard, "The Mechanism of Activation of 4-Hydroxycyclophosphamide," J. Med. Chem., 30:427-431 (1987).	*
		Cooper et al., "Use of Carbohydrate Derivatives for Studies of Phosphorus Stereo-chemistry. Part II. Synthesis and Configurational Assignments of 1,-3,2-Oxathiaphosphorinan-2-ones and 1,3,2-Dioxaphosphorinan-2-thiones," J. Chem. Soc., Perk. Trans. 1, (10):1049-1052 (1974).	
		De Clercq et al., "A Novel Selective Broad-spectrum Anti-DNA Virus Agent," Nature, 323:464-467 (1986).	
0		Farquhar et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	

Examiner Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form	1449A/PTO		Co	mplete if Known
INFORMATIO	ON DISCLO	SURF	Application Number	09/518,501
ì			Filing Date	March 3, 2000
STATEMEN'	I BY APPL	ICANI	First Named Inventor	Erion et al.
			Group Art Unit	1624
(use as many sheets as necessary)		Examiner Name	T. McKenzie	
2	of	3	Attorney Docket Number	032465.00013.RCE (CIP1)

	NON PATENT LITERATURE DOCUMENTS						
Exami Initials		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
*	/		Friis and Bundgaard, "Prodrugs of Phosphates and Phosphonates: Novel Lipophilic α-acyloxyalkyl Ester Derivatives of Phosphate- or Phosphonate Containing Drugs Masking the Negative Charges of these Groups," <u>Euro. J. Pharm. Sci.</u> , 4:49-59 (1996).				
			Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from 1-Menthone," <u>Tetrahedron</u> , 28(41):4843-4846 (1987).				
			Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," <u>JACS</u> , 79:430-436 (1957).				
			Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996).				
		•	Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995).				
			Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986).				
			McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993).				
			Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," <u>J. Org. Chem.</u> , 42(9):1549-1555 (1977).				
			Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," <u>J. Am. Chem. Soc.</u> , 112:6936-3942 (1990).				
4			Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoalkyl Diisopinocampheylborinate Intermediates," <u>Tetrahedron</u> , 38(5):761-764 (1997).				

Examiner Date Considered 7/8/00

*EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1	449A/PTO		Complete if Known	
NFORMATIC	N DISCLO	SURE	Application Number	09/518,501
			Filing Date	March 3, 2000
STATEMENT	BY APPL	ICANI	First Named Inventor	Erion et al.
	•		Group Art Unit	1624
(use as m	any sheets as n	ecessary)	Examiner Name	T. McKenzie
3	of	3	Attorney Docket Number	032465,00013.RCE (CIP1)

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
81	1	Starrett, Jr. et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., 37:1857-1864 (1994).				
		Thomson et al., "Synthesis, Bioactivation and Anti-HIV Activity of the Bis(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Esters of the 5'-monophosphate of AZT," J. Chem. Soc., Perk. Trans. 1, (11):1239-1245 (1993).				
		Weber and Waxman, "Activation of the Anti-cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes," <u>Biochem. Pharm.</u> , 45(8):1685-1694 (1993).				
		Zon et al., "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of cis- and trans-4-Hydroxycyclophosphamide with Aldophosphamide and Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," J. Med. Chem. 27:466-485 (1984).				

Examiner Date Signature <u>Considered</u>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw one through offation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

